Cargando…

重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342188/
https://www.ncbi.nlm.nih.gov/pubmed/29365407
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.017
_version_ 1783555397472223232
collection PubMed
description
format Online
Article
Text
id pubmed-7342188
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73421882020-07-16 重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2017-12 /pmc/articles/PMC7342188/ /pubmed/29365407 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.017 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性
title 重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性
title_full 重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性
title_fullStr 重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性
title_full_unstemmed 重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性
title_short 重组人血小板生成素联合激素及环孢素A治疗免疫相关性血细胞减少症20例近期疗效及安全性
title_sort 重组人血小板生成素联合激素及环孢素a治疗免疫相关性血细胞减少症20例近期疗效及安全性
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342188/
https://www.ncbi.nlm.nih.gov/pubmed/29365407
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.017
work_keys_str_mv AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng
AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng
AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng
AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng
AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng
AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng
AT zhòngzǔrénxuèxiǎobǎnshēngchéngsùliánhéjīsùjíhuánbāosùazhìliáomiǎnyìxiāngguānxìngxuèxìbāojiǎnshǎozhèng20lìjìnqīliáoxiàojíānquánxìng